Cupid shares jump 6%, extend rally to 11% in one week as company raises FY27 revenue guidance after strong Q1 biz update
According to the filing with the exchange, the company is on track to deliver revenue exceeding Rs 150 crore in the first quarter of FY27, marking one of the strongest quarterly performances in its history.
Cupid said that, driven by this exceptional start to the financial year and improved visibility across international & domestic markets, the management has revised its FY27 revenue outlook upward by a minimum of 10%, which means that the company expects FY27 revenue of more than Rs 660 crore, up from its earlier guidance of Rs 600 crore.
Also Read | Diamond Power Infrastructure shares jump 10% after Rs 435 crore order for Hyderabad data centre projects
The revised outlook reflects growing confidence in the company’s diversified business model, expanding global opportunity pipeline and increasing operating scale across multiple business verticals.
According to the company, growth is expected to be supported by expanding opportunities in international B2B healthcare markets, driven by demand from institutional buyers, private sector customers and government procurement programmes.
This outlook is further supported by the commencement of its long-term supply agreement with the Partnership for Supply Chain Management (PFSCM), Netherlands, which the company said strengthens its position in global healthcare procurement.The company also highlighted growing opportunities in its lubricant portfolio, driven by increasing acceptance across institutional and consumer channels. It said its consumer business offers significant long-term potential as it continues to expand its personal care and wellness brand across modern trade, organised retail and pharmacy networks across Bharat.
Cupid said it sees strong order visibility across private markets, institutional business and international tenders spanning multiple geographies. It expects sustained growth in its male and female condom businesses, driven by expanded manufacturing capacity, new customer additions and a broader market reach built over the past 12 months.
The company also said it is making steady progress in its In Vitro Diagnostics (IVD) business. While near-term growth expectations remain conservative, it expects the segment to become a meaningful contributor over the coming years, supported by regulatory approvals, new product launches and continued commercialisation efforts.
“Our strong start to FY27 reflects the transformation Cupid has undergone over the past few years. We have built a diversified business with multiple growth engines that are now beginning to scale together,” said Aditya Kumar Halwasiya, Chairman and Managing Director, Cupid.
Also Read | Vedanta and TCS among 5 stocks with highest dividend yield. Check details
Halwasiya further said, “We are seeing strong momentum across our international B2B business, supported by expanding opportunities in private markets, institutional procurement, and government tenders across the world. Our strategic relationship with PFSCM has commenced on a very encouraging note and further strengthens our long-term position in global healthcare procurement.”
He added that, backed by a strong order book, improving visibility across international markets and a robust pipeline of opportunities, the company has revised its medium-term revenue outlook upward. “At the same time, we believe our projections remain conservative, leaving room for additional upside as execution continues and new opportunities materialise,” he said.
In the last two weeks, the shares of Cupid were up 16.14% and by over 52% in the last month.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
